The promise of antisense drugs
lies in the theory that they work on a specific target disease without causing significant side effects.
The patent covers the use of both single-stranded and double-stranded (siRNA) antisense drugs
complementary to any site of the mRNA of human apoB regardless of their chemistry or antisense mechanism of action.
Planning for Tapping a Successful Antisense Drug
As reported earlier this year, ISIS 104838 accumulated in synovial tissue in a dose-dependent manner, reducing TNF-alpha mRNA levels in patients with RA who received 300 mg of the second-generation antisense drug
(see company press release from September 18, 2003).
There are currently 82 biotech drags approved for use in the US market: 42 therapeutic proteins, 27 small molecule drugs, 12 antibodies and one antisense drug
. And the pipeline boasts more than 400 promising candidates in a wide range of therapeutic categories including AIDS, cancer, diabetes, infectious diseases, genetic disorders, heart disease, neurological and respiratory disorders, and more.
In contrast to conventional chemotherapy for the disease, the antisense drug
so far seems safe enough for patients to take in a doctor's office rather than in the hospital, says Bayever.
(NASDAQ: IONS) have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug
candidates for a broad range of neurological diseases, the companies said.
Monia, chief operating officer, senior vice president of antisense drug
discovery and translational medicine at Ionis Pharmaceuticals.
Isis' patent estate covers fundamental oligonucleotide chemistries; antisense drug
discovery (multiple mechanisms); antisense therapeutics; manufacturing; formulations, and delivery of oligonucleotide therapeutics, as well as Ibis' RNA technology for the identification of infectious organisms.
OGX-011 is a second-generation antisense drug
designed to specifically inhibit the production of clusterin, a cell-survival protein that is up-regulated in response to standard anti-cancer treatments.
This information on antisense transcription will also provide significant advantages in the design and analysis of functional genomic experiments, as well as for target discovery, protein pathways and antisense drug
design, and we have begun seeking collaborators for these applications.
Ionis designed IONIS-HTTRx (RG6042), a Generation 2+ antisense drug
, to specifically reduce the production of all forms of the huntingtin protein, including mHTT.